+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)



Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)



Annals of the Rheumatic Diseases 73(2): 407-413



The Swedish Early Psoriatic Arthritis Register describes the course of early psoriatic arthritis (PsA) in a real life clinical setting in Sweden. The aim of this study was to obtain information on predictors of clinical outcomes over a 5-year period with special focus on effects of gender, joint patterns, diagnostic delay and initial disease activity. In six centres, patients with signs suggestive of PsA were included in the Swedish Early Psoriatic Arthritis Register within 2 years of symptom onset. CASPAR (classification for psoriatic arthritis) criteria were fulfilled by 197 patients who had passed the 5-year follow-up. Disease activity was measured by the Disease Activity Score including 28 joints (DAS28) and the Disease Activity Index for Psoriatic Arthritis (DAPSA). Remission and minimal disease activity (MDA) were used as outcome measures. Mean age at inclusion was 46 years, younger in male than female patients (43 vs 48 years). Mean DAS28 was 3.7 and 3.0 at inclusion and 2.8 and 2.1 at follow-up for women and men, respectively-significantly higher in women at both visits. Likewise, DAPSA scores were significantly higher in women. The degree of improvement (change in DAS28 and DAPSA) was similar. Men achieved MDA or remission (50% vs 33%, 25% vs 13%, respectively) more often, and women had significantly more polyarthritis at inclusion (49% vs 27%) and after 5 years (25% vs 15%). Axial or mono/oligoarticular disease was predominant in men. Independent predictors of MDA at the 5-year follow-up were: shorter symptom duration; greater general well-being (global visual analogue scale); and low Health Assessment Questionnaire at inclusion. In early PsA, short delay between onset of symptoms and diagnosis, preserved function, and male gender are the most important predictors of favourable clinical outcome at the 5-year follow-up. Early recognition of PsA and active treatment may be important, particularly in women with polyarticular disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052762653

Download citation: RISBibTeXText

PMID: 23355078

DOI: 10.1136/annrheumdis-2012-201972


Related references

The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis. Journal of Rheumatology 35(4): 668-673, 2008

DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort. Clinical and Experimental Rheumatology 35(6): 936-942, 2017

AB0949Treatment in mono-/oligo- and polyarthritic patients; a study on the swedish early psoriatic arthritis cohort (SWEPSA). Annals of the Rheumatic Diseases 71(Suppl 3): 692.19-693, 2013

Development and early experiences of a Swedish psoriatic arthritis register. Scandinavian Journal of Rheumatology 31(4): 221-225, 2002

Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?. Modern Rheumatology 21(1): 106-108, 2011

THU0419Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-Up from the Psoriatic Arthritis Clinical Development Program. Annals of the Rheumatic Diseases 74(Suppl 2): 350.1-350, 2015

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Annals of the Rheumatic Diseases 67(3): 364-369, 2008

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis and Rheumatism 56(8): 2698-2707, 2007

Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. Rheumatology 54(1): 200-202, 2015

The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. Bmc Musculoskeletal Disorders 14: 101, 2013

Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis and Rheumatism 64(10): 3150-3155, 2012

Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Journal of Rheumatology 36(2): 368-370, 2009

Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis and Rheumatism 57(8): 1560-1563, 2007

SAT0573Clinical and Treatment Patterns in Early Psoriatic Arthritis: Comparison with Early Rheumatoid Arthritis in a Recent Onset Arthritis Cohort: Table 1. Annals of the Rheumatic Diseases 74(Suppl 2): 868.1-868, 2015

Development and early experiences of a psoriatic arthritis register. Journal of Rheumatology 27(Suppl. 59): 34, 2000